Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Stock Information for Lineage Cell Therapeutics, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lineage Cell Therapeutics, Inc.

Longeveron to Participate in Three Longevity/Aging Investment Conferences
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Longeveron Announces 1-for-10 Reverse Stock Split
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.